Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERSNOMAD Power Solutions, Inc. ("NOMAD" or the "Company") (Nasdaq: NMAD) (formerly LIXTE Biotechnology Holdings), a provider of transportable, utility-grade battery energy storage systems through its wholly owned subsidiary NOMAD Transportable Power Systems, today announced that the Company’s Special Meeting of Stockholders (the “Special Meeting”), originally convened at 1:00 PM Eastern Time on September 4, 2026, was adjourned without conducting any business and will reconvene on October 2, 2026 at 1:00 PM Eastern Time, in order to provide the Company additional time to complete and finalize its Nasdaq listing application.
- Glancy Prongay Wolke & Rotter LLPCapricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitGlancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Capricor Therapeutics, Inc. IF YOU SUFFERED A LOSS ON YOUR CAPRICOR THERAPEUTICS, INC. INVESTMENTS,...
- Lupin PharmaceuticalsLupin Receives U.S. FDA Approval for Modafinil Tablets, USPGlobal pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA)...
- UNCY INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Unicycive Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the FirmA shareholder class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive”) (NASDAQ: UNCY). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) Unicycive had not inspected its third-party manufacturing vendor’s facility or otherwise audited the facility’s compliance with current good manufacturing practices; (2) as a result, Unicycive lacked a reasonable basis to believe that the vendor had resolved the FDA’s cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor’s facility’s manufacturing practices; (4) as a result of the foregoing, the regulatory approval of oxylanthanum carbonate was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ positive statements about Unicycive’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
- Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)The global renal denervation market is projected to grow from USD 1.44 billion in 2026 to USD 8.64 billion by 2036, at a CAGR of 19.6%. Growth is driven by rising resistant and uncontrolled hypertension, positive clinical trial results, regulatory approvals, reimbursement expansion, and advances in radiofrequency, ultrasound, and micro-infusion technologies. North America leads the market, while Asia-Pacific is expected to grow fastest. The report analyzes key products, technologies, indications, end users, regions, competitive strategies, and companies shaping this minimally invasive hypertension treatment market.
- Kaplan Fox & Kilsheimer LLPKaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by...
- RADIATION BUSINESS SOLUTIONSRADIATION BUSINESS SOLUTIONS ENCOURAGES INDUSTRY-WIDE FEEDBACK ON PROPOSED MEDICARE PAYMENT CHANGESRadiation Business Solutions (RBS) urges radiation oncology providers and industry leaders nationwide to join ongoing advocacy efforts concerning the CMS proposed CY 2027 Medicare Physician Fee Schedule. While CMS has proposed increases for...
- Tyra BiosciencesTyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that...
- Alumis Inc.Alumis to Participate in Upcoming September Investor ConferencesAlumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:
- Iovance Biotherapeutics to Present at Upcoming ConferencesIovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
- Intellia Therapeutics, Inc.Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceIntellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET.